Current understandings of the basic principles of the molecular machinery underlying cardiac failure development are extremely important for regenerative therapies and precision medicine. Although diagnostic algorithm for heart failure determination is well established, there are expectations that genetic and epigenetic biomarkers incorporated into traditional heart failure risk scores can improve stratification of the patients at higher risk of the disease which opens new approaches for personal precise care of cardiac failure. Additionally, epigenomics has been found to be a crucial mechanism in post-transcriptional regulation of biomechanical stress, oxidative insult, inflammation, fibrosis, reparation, and regeneration, which are dysregulated in failing hearts and related to numerous co-morbidities in known heart failure. There are several promising targets for therapeutic approaches in heart failure that are considered as methods to improve clinical outcomes of the disease, such as direct cardiac reprogramming, cell transplantation, stimulation of resident cardiomyocytes, proliferation, and inhibition of cardiomyocyte death.
This Research Topic welcomes original research and review articles on the subject of epigenetics and genetic regulation in heart failure developing. We also welcome methodological papers that analyse epigenetic biomarkers and papers that present new epigenetic biomarker-based models that could be effective in the prediction of heart failure.
Submissions are encouraged that discuss new epigenetic biomarkers such as single nucleotide polymorphisms, non-coding micro RNAs, DNA methylation, and histone modification as well as articles that clarify novel approaches in epigenetics and genetic regulation of both embryonic stem cells and induced pluripotent stem in heart failure. Articles that cover new technologies including advanced bioinformatics and computational predictions are also welcome. Finally, we also welcome papers that cover epigenetic mechanisms underlying diagnostic strategies and the use of therapeutic epigenetic molecules or epidrugs in patients at the risk of heart failure development.
Other potential themes include but are not limited to the following:
1) Conception and clinical implementation of epigenetic and genetic biomarker-based risk assessment in heart failure.
2) Cardiac transcriptional remodeling and hypertrophy.
3) DNA methylation and histone modification in heart failure and hypertrophy.
4) MicroRNAs signature in cardiac remodeling and heart failure.
5) Epigenetics and co-morbidities in different etiological subtypes of heart failure.
6) Endogenous cardiac regeneration via manipulating gene expressions.
7) Gene card in heart failure.
8) Pharmacological inhibition of transcriptional machinery.
9) Regenerative strategies in prevention of cardiac remodeling and heart failure.
Current understandings of the basic principles of the molecular machinery underlying cardiac failure development are extremely important for regenerative therapies and precision medicine. Although diagnostic algorithm for heart failure determination is well established, there are expectations that genetic and epigenetic biomarkers incorporated into traditional heart failure risk scores can improve stratification of the patients at higher risk of the disease which opens new approaches for personal precise care of cardiac failure. Additionally, epigenomics has been found to be a crucial mechanism in post-transcriptional regulation of biomechanical stress, oxidative insult, inflammation, fibrosis, reparation, and regeneration, which are dysregulated in failing hearts and related to numerous co-morbidities in known heart failure. There are several promising targets for therapeutic approaches in heart failure that are considered as methods to improve clinical outcomes of the disease, such as direct cardiac reprogramming, cell transplantation, stimulation of resident cardiomyocytes, proliferation, and inhibition of cardiomyocyte death.
This Research Topic welcomes original research and review articles on the subject of epigenetics and genetic regulation in heart failure developing. We also welcome methodological papers that analyse epigenetic biomarkers and papers that present new epigenetic biomarker-based models that could be effective in the prediction of heart failure.
Submissions are encouraged that discuss new epigenetic biomarkers such as single nucleotide polymorphisms, non-coding micro RNAs, DNA methylation, and histone modification as well as articles that clarify novel approaches in epigenetics and genetic regulation of both embryonic stem cells and induced pluripotent stem in heart failure. Articles that cover new technologies including advanced bioinformatics and computational predictions are also welcome. Finally, we also welcome papers that cover epigenetic mechanisms underlying diagnostic strategies and the use of therapeutic epigenetic molecules or epidrugs in patients at the risk of heart failure development.
Other potential themes include but are not limited to the following:
1) Conception and clinical implementation of epigenetic and genetic biomarker-based risk assessment in heart failure.
2) Cardiac transcriptional remodeling and hypertrophy.
3) DNA methylation and histone modification in heart failure and hypertrophy.
4) MicroRNAs signature in cardiac remodeling and heart failure.
5) Epigenetics and co-morbidities in different etiological subtypes of heart failure.
6) Endogenous cardiac regeneration via manipulating gene expressions.
7) Gene card in heart failure.
8) Pharmacological inhibition of transcriptional machinery.
9) Regenerative strategies in prevention of cardiac remodeling and heart failure.
